Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining surgery with chemotherapy may kill more tumor cells. It is not yet known whether chemotherapy before surgery is more effective than chemotherapy after surgery in treating ovarian, peritoneal, or fallopian tube cancer.

PURPOSE: This randomized phase III trial is studying chemotherapy given before surgery to see how well it works compared to chemotherapy given after surgery with or without additional surgery in treating patients with stage III or stage IV ovarian cancer, peritoneal cancer, or fallopian tube cancer.


Options:
A: Arm Label: Arm I PDS and chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PDS (Primary Debulkdung Surgery), Procedure: 6 cycles of standard chemotherapy | Arm Label: Arm II Timing of surgery after 3 cycles of SOC CTX; Type: EXPERIMENTAL; Interventions: Procedure: Timing of surgery after 3 cycles of standard NACT, IDS, Procedure: IDS, Drug: 3 cycles of standard chemotherapy | Intervention Type: PROCEDURE; Name: PDS (Primary Debulkdung Surgery); Assigned to Arm(s): Arm I PDS and chemotherapy | Intervention Type: PROCEDURE; Name: 6 cycles of standard chemotherapy; Assigned to Arm(s): Arm I PDS and chemotherapy | Intervention Type: PROCEDURE; Name: Timing of surgery after 3 cycles of standard NACT, IDS; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX | Intervention Type: PROCEDURE; Name: IDS; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX | Intervention Type: DRUG; Name: 3 cycles of standard chemotherapy; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX
B: Arm Label: Primary debulking surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Primary Debulking Surgery + Adjuvant Chemotherapy | Arm Label: Interval debulking surgery; Type: EXPERIMENTAL; Interventions: Drug: Neoadjuvant chemotherapy + Interval Debulking Surgery | Intervention Type: DRUG; Name: Neoadjuvant chemotherapy + Interval Debulking Surgery; Assigned to Arm(s): Interval debulking surgery | Intervention Type: PROCEDURE; Name: Primary Debulking Surgery + Adjuvant Chemotherapy; Assigned to Arm(s): Primary debulking surgery
C: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A
D: Arm Label: Arm I (placebo, paclitaxel, carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm II (placebo, paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm III (paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab)

Answer: C